3,844 reports of this reaction
2.1% of all TACROLIMUS EXTENDED RELEASE CAPSULES reports
#8 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #8 most commonly reported adverse reaction for TACROLIMUS EXTENDED RELEASE CAPSULES, manufactured by Astellas Pharma US, Inc.. There are 3,844 FDA adverse event reports linking TACROLIMUS EXTENDED RELEASE CAPSULES to CYTOMEGALOVIRUS INFECTION. This represents approximately 2.1% of all 181,869 adverse event reports for this drug.
TACROLIMUS EXTENDED RELEASE CAPSULES has an overall safety score of 92 out of 100. Patients taking TACROLIMUS EXTENDED RELEASE CAPSULES who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for TACROLIMUS EXTENDED RELEASE CAPSULES, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for TACROLIMUS EXTENDED RELEASE CAPSULES:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 3,844 FDA reports for TACROLIMUS EXTENDED RELEASE CAPSULES. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 2.1% of all adverse event reports for TACROLIMUS EXTENDED RELEASE CAPSULES, making it a notable side effect.
If you experience cytomegalovirus infection while taking TACROLIMUS EXTENDED RELEASE CAPSULES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.